<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00889538</url>
  </required_header>
  <id_info>
    <org_study_id>Glutathione-KCPCRU-01</org_study_id>
    <nct_id>NCT00889538</nct_id>
  </id_info>
  <brief_title>Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior Problems</brief_title>
  <official_title>Double-Blind, Placebo-Controlled, Crossover Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior Problems</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cumberland Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norton Healthcare</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, placebo-controlled crossover study to evaluate the safety and&#xD;
      efficacy of glutathione alone or glutathione, vitamin C and NAC treatment in children with&#xD;
      autism who also have severe behavior problems. The investigators hypothesis is that children&#xD;
      with autism will show improvement in both learning capabilities and behavior with either&#xD;
      glutathione, or glutathione, vitamin C and NAC therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single center, double-blind, randomized pilot study in children and&#xD;
      adolescents with autism and severe behavior disorders. All subjects will undergo initial&#xD;
      screening procedures to determine eligibility. They will then be randomized to either 8 weeks&#xD;
      of placebo or 8 weeks of glutathione or glutathione, vitamin C and N-acetylcysteine. They&#xD;
      will receive intravenous treatment weekly and will have ongoing behavioral studies during&#xD;
      this period. Following 8 weeks of therapy, they will have a week without treatment then will&#xD;
      cross-over to the alternate therapy for weekly intravenous infusions and behavioral testing.&#xD;
      In addition to baseline hematology and chemistries, baseline oxidized and reduced glutathione&#xD;
      will be measured. These parameters will be repeated at the end of each 8 week course of&#xD;
      therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in both developmental skills and behavior with either glutathione or glutathione, Vitamin C and N-acetylcysteine therapy as compared to placebo therapy. Subjects will also be monitored using clinical and laboratory safety parameters.</measure>
    <time_frame>4 months</time_frame>
    <description>Improvement in both developmental skills and behavior measured using validated scales in subjects receiving either glutathione, glutathione/Vitamin C/N-acetylcysteine or placebo measured at baseline, 9 weeks and at the end of study in a double-blind cross-over design.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response to glutathione (changes in behavior) will correlate with the glutathione level (GSH) and GSH:GSSG ratio</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to glutathione (changes in behavior) will correlate with the glutathione level (GSH) and GSH:GSSG ratio</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to glutathione (changes in behavior) will correlate with the glutathione level (GSH) and GSH:GSSG ratio</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Autism</condition>
  <condition>Severe Behavior Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Randomized to placebo or treatment (glutathione or glutathione/vit C/NAC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glutathione</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized to placebo or treatment (glutathione or glutathione/vit C/NAC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glutathione, Vit C and NAC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized to placebo or treatment (glutathione or glutathione/vit C/NAC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>50 mL of 1/2 normal saline IV</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glutathione</intervention_name>
    <description>glutathione 600 mg IV</description>
    <arm_group_label>Glutathione</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glutathione, vit C and NAC</intervention_name>
    <description>Glutathione 600 mg IV Vitamin C 2000 mg IV N-acetylcysteine 20 mg/kg IV (max dose = 600 mg) Mix above three in 1/2 NS for a total volume of 50 mL</description>
    <arm_group_label>Glutathione, Vit C and NAC</arm_group_label>
    <other_name>NAC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 5 to 16 years, inclusive&#xD;
&#xD;
          -  Diagnosed with autism using the ADI-R (Autism Diagnostic Interview-Revised)&#xD;
&#xD;
          -  ABC Irritability/Agitation subscale score (Aberrant Behavior Checklist Subscale) ≥ 18&#xD;
&#xD;
          -  CGI-S score (Clinical Global Impression-Severity Scale) ≥ 4&#xD;
&#xD;
          -  Must be drug naïve or on a stable dose of medication(s) and educational/behavioral&#xD;
             interventions for one month prior to participation&#xD;
&#xD;
          -  Parent/legal guardian must provide written consent and required research authorization&#xD;
             (i.e. HIPAA) prior to the performance of any study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of another disorder on the autism spectrum including PDD-NOS (Pervasive&#xD;
             Developmental Disorder Not Otherwise Specified), Asperger's, and Rett's Syndrome&#xD;
&#xD;
          -  Patient with a known cause of autism such as Fragile X&#xD;
&#xD;
          -  Evidence of significant renal dysfunction (e.g. GFR estimated by the Schwartz formula&#xD;
             &lt; 50 mL/min or serum creatinine &gt; 2.5 X upper limit of normal for age)&#xD;
&#xD;
          -  Evidence of significant hepatic dysfunction (serum transaminases &gt; 2.5 X the upper&#xD;
             limit of normal)&#xD;
&#xD;
          -  Known hypersensitivity to glutathione, vitamin C or NAC&#xD;
&#xD;
          -  Pregnant or lactating female&#xD;
&#xD;
          -  Inability of subject and parent to be able to comply with requirements for study&#xD;
             visits and procedures&#xD;
&#xD;
          -  Presence of major mental illness&#xD;
&#xD;
          -  History of antioxidant supplementation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia G. Williams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Janice E. Sullivan, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KCPCRU</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>April 28, 2009</study_first_submitted>
  <study_first_submitted_qc>April 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2009</study_first_posted>
  <last_update_submitted>December 6, 2016</last_update_submitted>
  <last_update_submitted_qc>December 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autism</keyword>
  <keyword>Severe Behavior Disorder</keyword>
  <keyword>Glutathione</keyword>
  <keyword>Antioxidants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Problem Behavior</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

